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Summary 
Recent in vitro studies have established that activated B cells express OX40 ligand (L), a mem- 
ber of the tumor necrosis factor/nerve growth factor family of cytokines, and become stimu- 
lated to proliferate and secrete immunoglobulin (Ig) after cross-linking of OX40L by its coun- 
terreceptor OX40, which is expressed on activated T cells. In the present study we investigated 
the in vivo role of this receptor-ligand pair for the interaction of T  and B cells in the course of 
the  T-dependent B  cell response against  2,4,6  trinitro-phenyl-keyhole limpet hemocyanin. 
First,  we showed that OX40 is maximally expressed by T  cells in the periarteriolar lymphoid 
sheath (PALS) 3 d after primary immunization. These OX40 + cells are located in close prox- 
imity to antigen-specific, activated B cells. Second, we demonstrated that blocking of OX40-- 
OX40L interaction with a polyclonal anti-OX40 antibody or with antibodies against  certain 
peptide sequences within its extraceUular domain resulted in a profound decrease of the anti- 
hapten IgG response, whereas the antihapten IgM response was grossly unchanged. Third, we 
showed that this antibody treatment leads to an 'inhibition of the development of PALS-associ- 
ated B  cell foci, whereas the formation of germinal centers remained intact.  Finally, our data 
suggest that, whereas B cell memory development was not impaired by anti-OX40 administra- 
tion, OX40-OX40L interaction seems to be crucial in the secondary immune response. We 
conclude from these data that the OX40-OX40L interaction in vivo is necessary for the differ- 
entiation of activated B cells into highly Ig-producing cells, but is not involved in other path- 
ways of antigen-driven B cell differentiation such as memory cell development in the germinal 
centers. 
T 
he differentiation of mature B  cells during the course 
ofa T cell-dependent humoral immune response con- 
sists  of Ig  isotype  switching  and  terminal  differentiation 
into plasma cells or memory B  cells.  A  number of studies 
have demonstrated that after initial stimulation through the 
antigen  receptor and  after contact help  from activated T 
helper cells, B cells follow a branched differentiation path- 
way (1-3). In the spleen, the branching takes place in the 
periarteriolar lymphoid sheath  (PALS) 1.  Some  cells  leave 
the PALS and enter the B  cell follicle to form oligoclonal 
germinal centers in which they divide rapidly, undergo af- 
finity maturation through somatic mutation, and eventually 
become memory B  or plasma cells.  In contrast, other cells 
IAbbreviations used in this paper: AFC, antibody-forming  B cell; AP, alka- 
line phosphatase; CD40L, CD40 ligand; HSA, heat stable antigen; HRP, 
horseradish peroxidase; NGF, nerve growth factor; PALS, perioarteriolar 
lymphoid sheath; TNP, 2,4,6 trinitro-phenyl. 
form PALS-associated B cell foci, which are largely respon- 
sible for the early primary humoral immune response (4). 
A number of  stimuli have been identified that are impor- 
tant for the initiation of the differentiation events occurring 
during a T-dependent, antigen-driven B cell differentiation 
(e.g., costimulation ofT cells through CD28  [5-7]; CD40 
ligand (L) L on activated T  cells [8]), indicating their possi- 
ble role in early B  cell activation. However, with the ex- 
ception of Ig isotype switching, which is made possible by 
stimulation through CD40 and guided by cytokines (9), the 
specific signals that drive a B cell towards terminal differen- 
tiation on the one hand or memory development on the 
other, have yet to be identified. In addition, it is unclear if 
the  different  B  cell  differentiation  pathways  mentioned 
above occur because of the presence of different precom- 
mitted mature B  precursor cells  (e.g.,  heat stable  antigen 
(HSA)tow versus HSAhig  h cells; 10) or because a single popu- 
lation of B precursor ceils receives different signals  during 
their stay in the PALS. 
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role of OX40-OX40L  interaction--a relatively novel re- 
ceptor-ligand pair--during the course of in vivo T-depen- 
dent B cell differentiation. OX40 is a member of the TNFRJ 
nerve  growth  factor  (NGF)  R  superfamily  of receptors 
and is expressed on  activated T  cells (11,  12),  whereas its 
ligand,  OX40L,  is found  on  activated B  cells (12,  13).  In 
previous studies we demonstrated that the cross-linking of 
OX40L  on  in  vitro  activated B  cells  resulted  in  an  en- 
hanced proliferation and a striking increase in Ig secretion 
(13).  In  addition,  we  showed  that  the  latter  effect  was 
probably brought about by the effect of OX40L cross-link- 
ing on the state of activation of the Ig 3'or enhancer (13). 
In  the  present  study  we  demonstrate  that  blocking  of 
OX40-OX40L  interaction in  vivo by multiple injections 
of anti-OX40  antibody results  in  a  profound  decrease  in 
the T  cell--dependent antibody response, without the inhi- 
bition of germinal center formation or B  cell memory de- 
velopment.  These  results  thus  suggest  a  critical  role  for 
OX40--OX40L  interaction in driving activated B  cells to- 
wards terminal differentiation into Ig-secreting plasma cells. 
Materials  and  Methods 
Cell Preparation, Culture Conditions and Flow Cytometric Analysis. 
6-9-wk-old female  BALB/c  mice  (National  Cancer  Institute) 
were  killed, their spleens  removed  and  digested by collagenase 
(400  U/ml,  Boehringer Mannheim,  Mannheim,  Germany)  plus 
DNase (12.5 ~g/ml; Boehringer Mannheim) at 37~  for 15 rain. 
The resulting splenocyte suspension was depleted of RBC by hy- 
potonic lysis with ACK lysing buffer (B&B Scott, West Warwick, 
RI). The cells collected after this treatment were applied to a T 
cell isolation column  (Pierce Chemical Co.,  Rockford,  IL)  ac- 
cording to the manufacturer's protocol. The resulting cell popu- 
lation  was  85-90%  positive  for  CD3  as  determined  by  flow 
cytometry using the FACScan  |  (Becton Dickinson &  Co.,  San 
Jose, CA). 
T  cells were incubated on anti-CD3r  (145-2Cll)-coated 12- 
well plates (Costar Corp., Cambridge, MA) at 37~  and 6% CO2 
in RPMI 1640 was supplemented with 10% FCS, 5% NCTC 109 
media  (Whittaker  M.  A.  Bioproducts,  Walkersville, MD),  20 
mM Hepes (NIH media unit), 2 mM r-glutamine (NIH media 
unit),  50  I~M  [3-mercaptoethanol  (Sigma  Chemical  Co.,  St. 
Louis, MO),  and  10  U/ml  penicillin/100  ~g/ml streptomycin 
(GIBCO BRL, Gaithersburg, MD). 
After the indicated periods of time, T  cells were analyzed for 
OX40  expression by flow cytometry using the  FACScan  |  and 
the  biotinylated polyclonal anti-OX40  antibody (described be- 
low), as well as streptavidin-PE, anti-CD4-FITC and anti-CD8- 
FITC antibodies (PharMingen, San Diego, CA). 
Preparation of 2,4,6 Trinitro-Phenyl Protein Derivatives.  TNP- 
(2,4,6 trinitro-phenyl) KLH or TNP-BSA were prepared as fol- 
lows. 20 mg lyophilized KLH (Pierce Chemical Co.) or 4.8 mg 
BSA (Sigma Chemical Co.) was dissolved in 4 ml potassium bo- 
rate buffer (0.25  M, pH, 9.2), and 3 or 6 mg TNBS (2,4,6-trini- 
trobenzyl sulfonic acid; Sigma Chemical Co.) and 16 t*1 sodium 
carbonate (1  M) were added. The reaction was allowed to take 
place overnight, after which the protein derivatives were dialyzed 
against PBS,  pH:  7.4.  TNP  protein derivatives were  frozen at 
-20~  until use. TNP-LPS was purchased from Sigma Chemical 
Co.  and  TNP-Ficoll was  kindly provided by Dr. John  Inman 
(Laboratory of Immunology, National Institutes of Health [NIH]). 
Preparation of OX40 Peptides.  The  following two peptide se- 
quences of the extracellular domain of the murine OX40 protein 
(12) were selected: P-OX-1106q23 and P-OX-2147_I64. These pep- 
tides were synthesized by the F-moc method (Dr. John Coligan, 
Laboratory of Molecular Structure, NIH) and conjugated to ma- 
leimide-activated KLH according to the manufacturer's protocol. 
The conjugates were dialyzed against PBS and used for the pro- 
duction ofantipeptide antibodies. 
Preparation of Anti-OX40 Antibodies.  100  p,g OX40-Ig fusion 
protein (12) or 2.5 mg P-OX-1- or P-OX-2-KLH in CFA was 
subcutaneously injected into 8-10-wk-old New Zealand White 
(NZW) rabbits. Serum was collected after 4 wk and analyzed for 
antibody titers by ELISA. In the case of the P-OX peptides,  animals 
were boosted with 1 mg P-OX-KLH twice before antisera were 
drawn after 7 wk. Antisera were subsequently treated with 45% 
saturated ammonium sulfate (Sigma Chemical Co.); the precipi- 
tate was dissolved in PBS and dialyzed against PBS overnight at 
4~  The resulting Ig-enriched antisera were subsequently affinity 
purified as follows. First, the antisera were depleted of anti-human 
Fcyl antibodies (only in the case ofantisera against OX40-Ig) by 
applying them to a column (model C10/10;  Pharmacia Biotech, 
Piscataway, NJ) containing human IgG1 (Calbiochem-Novabio- 
chem Corp., San Diego, CA)-coated, CnBr-activated Sepharose 
beads  (Pharmacia Biotech).  Second,  the  resulting antisera were 
run  over  another  C10/10  column,  that  contained  OX40-1g- 
coated Sepharose beads; bound antibodies were eluted from the 
column with a 100-mM glycine, pH 2.5, wash, which was col- 
lected in 1 M  Tris-HC1, pH 7.4. Third, after another precipita- 
tion step with 45%  saturated ammonium sulfate,  the precipitate 
was  dissolved and  dialyzed as  mentioned  above.  The  resulting 
polyclonal rabbit anti-murine OX40 or P-OX antibody-contain- 
ing solutions were checked for their ability to bind to OX40 by 
ELISA and  Western blot  and  were  found  to  contain  minimal 
(<5%)  anti-human  [gG1  activity (in the  case  of anti-OX40-Ig 
antibodies). The purity was  assessed by SDS-PAGE analysis and 
the protein concentration was determined using the Bradford as- 
say (14). The purified antibodies were frozen at -20~  until use. 
For immunohistochemistry and FACS  |  analysis, the anti-OX40 
control 
48h  24h 
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Figure  1.  Expression of OX40 by in vitro activated T  cells.  Splenic T 
cells  were  incubated on anti-CD3-coated  12-welt plates and examined 
for the expression of OX40 after the indicated incubation periods by flow 
cytometry using the biotinylated rabbit anti-OX40 antibody (see Materi- 
als and Methods) or rabbit  lgG as control.  2AG2 was used to  elimated 
binding to Fc-receptors. Results represent two independent experiments. 
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Corp.) were biotinylated using Biotin-X-NHS (Boehringer Mann- 
helm) according to the manufacturer's protocol. 
In Vivo Protocol  for Hapten-specific  Antibody Production.  TNP-KLH, 
TNP-Ficoll, or TNP-LPS (100 ~g each in CFA) was injected in- 
traperitoneally into 6-8-wk-old female BALB/c mice (NCI, NIH). 
The animals were subsequently administered 200  ~g rabbit anti- 
OX40  or  rabbit  IgG  as  a  control  (Calbiochem-Novabiochem 
Corp.) daily on days  1-6 after immunization. These antibody con- 
centrations  were  found  to  be  effective as  previously  described 
(13).  Serum was collected on days 7,  10,  17, and 24. Serurn con- 
centrations  of anti-TNP-specific  antibodies were  determined  as 
described below. 
Assay for Anti-TNP-Specific  Ig.  0.3  mg/ml TNP-BSA in car- 
bonate buffer, pH 9.0,  was bound to 96-well ELISA plates, that 
were  subsequently  blocked  with  1%  BSA  in  PBS,  after  which 
murine sera from the anti-OX40-treated or from the control mice, 
diluted in PBS containing 1% BSA (from 1:100 to  >1:100,000), 
were incubated for 2 h  at 37~  The plates were then washed and 
goat  anti-murine  IgM,  IgG1,  IgG2a,  IgG2b,  IgG3,  IgA,  or  IgE 
conjugated  to  alkaline  phosphatase  (AP)  (1:500;  Southern  Bio- 
technology Associates,  Birmingham,  AL;  IgE-AP,  PharMingen) 
was  added.  Color reactions  were  performed using AP  substrate 
(Sigma  Chemical  Co.)  in  diethanolamine  buffer,  pH:  8.5.  To 
compare different specimens, the OD reading at 490 nm from the 
1:400 (or 1:1000 in the case oflgG1) dilution was evaluated. This 
was demonstrated to be well within the linear part of the titration 
CHIVe. 
Immunohistochemistry.  Mice treated intraperitoneally with TNP- 
KLH (100 la.g in CFA) and anti-OX40 antibodies (200 I-~g  for 6 d), 
rabbit lgG or PBS as controls were killed on day 7 or 11, respec- 
tively. The spleens were removed, frozen in OCT-Freezing Me- 
dia  (Miles, Elkhart,  IN)  on dry ice and kept at  -80~  For the 
staining with anti-OX40  antibodies,  mice were  inoculated with 
100 I~g i.v. TNP-KLH and the spleens were removed on days 2, 
3, 4, 5, 7, and 10.  Frozen tissues  were subsequently cut into 6-9- 
Ixm sections, transferred to glass slides, dried overnight, and kept 
at  -80~  until use.  Subsequently, the frozen sections were fixed 
in  cold acetone  for  5  rain,  rehydrated  in  PBS  for  10  rain,  and 
blocked with  1% BSA and 3% goat serum for 60 min.  This step 
was  followed by  a  60-rain  incubation  period  with  biotinylated 
anti-OX40, anti-CD4-FITC, or biotinylated anti-IgD (PharMin- 
gen). PNA-biotin (Pierce Chemical Co.) was used to detect ger- 
minal  centers.  As  secondary  substances,  streptavidin-AP  (Boeh- 
finger Mannheim),  streptavidin-PE,  and  streptavidin-horseradish 
peroxidase (HR.P)  (PharMingen)  or streptavidin-Texas red (Am- 
ersham,  Arlington Heights, IL) were used.  Anti-TNP---specific B 
cells were visualized by a TNP-AP conjugate, that was prepared 
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Figure  2.  After  systemic  immunization,  OX40  is  ex- 
pressed by CD4  + T  cells, which are in close proximity to 
specific AFCs.  BALB/c mice were  injected with  100  I~g 
TNP-KLH and their spleens removed and frozen on dry ice 
3  d  after  immunization.  Immunohistochemistry  was  per- 
formed  on  frozen  sections  as  described  in  Materials  and 
Methods.  (A)  Cryosections  were stained  with biotinylated 
anti-OX40,  washed,  and  subsequently  incubated  with 
streptavidin-AP.  The  Vector red  substrate  kit  for AP was 
used  for  color reaction  and  the  tissue was  counterstained 
with 5% methyl-green.  OX40  + cells are located in the inner 
and  outer PALS (P). No OX40  + cells were detected  in B 
cell follicles (F). (B) Splenic frozen sections were incubated 
with rat  anti-mouse  CD4-FITC and  the biotinylated  anti- 
OX40  antibody.  After  that,  a  second  incubation  with 
streptavidin-Texas  red  followed.  Fluorescence  microscopy 
was performed on  the Zeiss  Axiophot microscope.  CD4  § 
cells  appear  green,  whereas  CD4/OX40  double-positive 
cells (green and red) appear yellow.  (C) Sections were incu- 
bated with biotinylated  anti-OX40 and TNP-AP conjugate, 
washed  and incubated  with streptavidin-HP,.P.  The Vector 
red substrate kit for AP (red) and the DAB kit (brown/black) 
was  used  for  color  reactions.  Photomicrograph  depicts 
OX40  + cells (brown~black) in  close proximity to  antibody- 
forming B cells (red). (A)  ￿  (B) ￿  and (C) ￿ A 
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Figure 3.  Administration of three different anti- 
OX40 antibodies inhibit the T  cell-dependent lgG 
but not IgM production and do not alter T-inde- 
pendent  responses.  BALB/c  mice  were  injected 
with  100  ~g i.p.  TNP-KLH  (T  cell-dependent), 
TNP-Ficoll (TI-2), and TNP-LPS  (TI-I) in CFA 
and either treated with anti-OX40 antibodies,  PBS, 
or control rabbit IgG (200 ~,g on days 1-6). Serum 
was collected at the indicated time points and anti- 
TNP-specific Ig was measured as described  in Ma- 
terials  and Methods.  No  difference  was  observed 
between the rabbit IgG and the PBS treated group 
(data not shown). (A) Anti-TNP~pecific IgG of all 
subclasses in response  to  TNP-KLH  after the ad- 
ministration ofanti-OX40 (left), anti-P-OX-1 (mid- 
dle), anti-P-OX-2 (right), or rabbit IgG was deter- 
mined  as  described  in  Materials  and  Methods. 
TNP-specific  IgA  and IgE  responses  were  below 
the detection limit.  The results represent the OD490 
readings  of two independent experiments for each 
of the three antibodies. ODs can only be compared 
within  each  column  because  experiments  were 
done separately. (B) Anti-TNP-specific IgM in response  to TNP-KLH was determined in the same mice as in A. The results represent the 0D490 read- 
ings of two independent experiments for each of the three antibodies.  (C) Anti-TNP-specific IgG 3 wk after immunization with TNP-Ficoll or TNP- 
LPS was deterrmned. No significant difference  in all IgG subclasses between the anti-OX40 and the rabbit IgG control group was detected.  Results de- 
pict the 0D4911 readings for total anti-TNP-IgG for two independent experiments for each antigen. 
as decribed elsewhere (15). The color reaction was induced using 
either Vector red substrate for AP or the diaminobenzoic-acid sub- 
strate for H/LP (Vector Laboratories, Inc., Burlingame, CA). Slides 
were  counterstained with 5% methyl-green for 3  rain, air-dried, 
and mounted in Permount (Fisher Scientific, Fair Lawn, NJ). Fluo- 
rescence microscopy was performed on the Axiophot microscope 
(Zeiss, Oberkochen  Germany).  The  resulting image was  printed 
on a color video printer (model UP-500; Sony, Tokyo, Japan). 
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Results 
Expression  of 0X40  In  Vitro and In  Vivo.  in initial stud- 
ies, we  determined the time course of expression of OX40 
on activated T  cells in vitro. Splenic T  cells were stimulated 
with  plate-bound  anti-CD3,  and  flow  cytometry  on  the 
cells was performed using the biotinylated rabbit anti-murine 
OX40  antibody (see Materials and Methods)  at  12,  24,  48, 
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72,  96,  and  120  h.  OX40 was absent in resting cells,  but 
was  expressed  on  activated T  cells  as  early as  12  h  after 
stimulation,  and as depicted in Fig.  1,  the peak expression 
was  observed  after  24  h.  In  addition,  the  expression  of 
OX40  remained  upregulated  throughout  the  investigated 
5-d incubation  period.  Finally,  both CD4 +  and  CD8 +  T 
cells  expressed OX40  after stimulation  with  anti-CD3  in 
vitro  (data  not  shown);  this  finding  is  in  agreement with 
those ofBaum et at. (16), but is in contrast to the initial de- 
scription of OX40 expression in the rat, in which such ex- 
pression is restricted to CD4 + T  cells (11). 
To determine the in vivo kinetics and expression pattern of 
OX40 on activated T  cells, we immunized female BALB/c 
mice with TNP-KLH and performed immunohistochemis- 
try on frozen spleen sections 2, 3, 4, 5, 7, and 10 d after in- 
jection.  Whereas no cells  in tissues  of unimmunized  mice 
and only a few cells stained positive for OX40 2 d after im- 
munization (data not shown), in tissues obtained from mice 
3 d after immunization, OX40 was expressed by many cells 
within the inner and outer parts of the splenic PALS, but 
not within B cell follicles, as shown in Fig. 2 A. No signif- 
icant OX40 expression was observed after day 4. A similar 
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expression pattern  with  even higher  numbers  of OX40 + 
cells was observed after a secondary immunization (data not 
shown). Furthermore, as illustrated in Fig. 2 B, OX40 was 
predominantly  expressed  on  CD4 +  T  cells,  with  few 
CD8 + T  cells expressing OX40 (data not shown). We also 
investigated the location of OX40 +  T  cells  in relation to 
TNP-specific  antibody-forming B  cells  (AFCs)  after pri- 
mary immunization  with  TNP-KLH.  Previous studies  in 
vivo have shown that TNP-specific AFCs in the PALS ex- 
press OX40L (12).  As illustrated in Fig. 2  C, some OX40 + 
T  cells and antigen-specific B cells lie in close proximity to 
each other, suggesting a possible interaction through OX40 
and its ligand on the B cell. 
Blocking the OX40-OX40L Interaction In Vivo Results in a 
Profound Inhibition of T  Celt-dependent Antibody  Production. 
We next investigated the role of the OX40-OX40L inter- 
action during the course of a primary humoral immune re- 
sponse against the T cell-dependent antigen, TNP-haptenated 
KLH. In these studies, we first generated specific polyclonal 
rabbit  anti-OX40  antibodies  using  either  the  OX40-Ig 
fusion protein or two 18-mer peptides (P-OX-1106_123  and 
P-OX-2147_164) derived from the predicted amino acid se- 
quence  of the extracellular domain  of murine  OX40  (12) 
to immunize NZW rabbits.  The resulting rabbit antisera were 
purified using affinity chromatography as described in Ma- 
terials and Methods. The specificity of these antibodies was 
confirmed by the  inhibition  of the  stimulatory effects of 
OX40-Ig  (described  in  13)  on  B  cell  functions  in  vitro 
(data not shown). As depicted in Fig. 3 A, the injection of 
rabbit IgG together with  TNP-KLH resulted  in  a  strong 
anti-TNP-IgG  response  that  did  not  differ from the  re- 
sponse to this antigen in PBS-treated mice (data not shown). 
However, sera from mice that were treated with the anti- 
OX40  antibody exhibited virtually no  antihapten-specific 
IgG antibody response of any of the mice IgG subclasses. 
The anti-P-OX-2 antibody also resulted in profound inhi- 
bition,  whereas anti-P-OX-1  only inhibited  this response 
by 50-75%,  depending on the subclass.  It is interesting to 
note  that,  as  shown  in  Fig.  3  B,  the  anti-TNP  IgM  re- 
sponse  was  not  altered  after  treatment  with  anti-OX40, 
anti-P-OX-1, or anti-P-OX-2. 
In complementary studies, we investigated whether anti- 
OX40  treatment  affected  T  cell-independent  B  cell  re- 
sponses.  Thus,  we  challenged  mice  with  TNP-Ficoll  or 
TNP-LPS,  which  are  known  T  cell-independent  (TI-2 
and  TI-1,  respectively)  B  cell  stimuli,  and  also  injected 
these mice with anti-OX40 antibody or control rabbit lgG. 
As shown in Fig. 3  C, the TNP-specific IgG response was 
not significantly changed by the anti-OX40 treatment. Fi- 
nally, we performed in situ staining for cytokines on frozen 
spleen sections (IL-2, IL-4, IL-5, and IFN-~/) from control 
and  anti-OX40-treated  mice  and  found  no  decrease  in 
cytokine-secreting T  cells  in the anti-OX40-treated mice 
compared to control mice (data not shown). 
Immunohistochemical  Studies after Anti-OX40  Treatment. 
In the  spleen,  antigen-driven  B  cell  differentiation  takes 
place  at  two  distinct  sites:  in  the  PALS-associated B  cell 
foci, in which isotype switching and the development orB Figure  4.  The  formation  of 
PALS-associated B  cell  foci  but 
not of germinal centers after sys- 
temic immunization  with TNP- 
KLH is inhibited by the adminis- 
tration  of anti-OX40.  BALB/c 
mice were injected  with 100 ~g 
i.p.  TNP-KLH in  CFA. Spleens 
were  removed  7  or  11  d  after 
immunization  and  immunohis- 
tochemistry  was  performed  as 
described in Materials and Meth- 
ods.  (A  and  B)  Cryosections 
from spleens 7 d after the immu- 
nization  were  incubated  with 
TNP-AP  and  biotinylated  anti- 
IgD. Streptavidin-H1KP was em- 
ployed  as  secondary  reagent. 
Vector  Red  (red)  and  DAB 
(brown~black) was  used  for color 
reactions.  Photomicrographs  de- 
pict TNP-specific AFCs (red) lo- 
cated  at  the  outer  hmit  of the 
PALS  (P)  after  treatment  with 
control rabbit  IgG  (A), whereas 
the administration  of anti-OX40 
antibodies  results in  the appear- 
ance of far fewer and more scat- 
tered  TNP-specific  AFCs  (/3). 
Arrow indicates an early germi- 
nal  center  containing  antigen- 
antibody  complexes.  Photomi- 
crographs  illustrate  results  of 
three  independent  experiments 
(X200).  (C and D) Cryosections 
from spleens 11  d after immuni- 
zation  were  incubated  with  bi- 
otinylated  PNA.  Streptavidin- 
HRP  was  used  as  secondary 
reagent  and  DAB  (brown~black) 
was  employed  for  color  reac- 
tions.  Typical  PNA  +  germinal 
centers  appeared  in  control- 
treated  mice  (C)  as  well  as  in 
anti-OX40-treated  mice  (D). 
Photomicrographs  illustrate  re- 
sults of three independent exper- 
iments.  (E  and  F)  Cryosections 
from spleens 11 d after immuni- 
zation  were  incubated  with  bi- 
otinylated  anti-lgD.  Streptavi- 
din-HRP was used as secondary 
reagent  and  DAB  (brown~black) 
was  employed  for  color  reac- 
tions. Typical IgD- germinal centers appeared in control-treated  mice (E) as well as in anti-OX40-treated mice (F). Photomicrographs  illustrate results of 
three independent  experiments.  (A, B, E, and F) X200; (C and D) X400. 
cells secreting  high  amounts  of Ig occurs  (days  3-10  after 
immunization),  and in germinal centers,  which are the site 
of isotype  switching,  as  well  as  somatic  mutation  and  B 
memory  cell  development  (days  7-21;  4).  Using  TNP- 
haptenated  AP,  we  followed the  appearance  of TNP-spe- 
cific B  cells in the PALS after in vivo challenge with TNP- 
KLH.  As shown  in  Fig.  4  A,  in  control  mice 7  d  after the 
i.p.  injection of TNP-KLH  in CFA, the formation of clus- 
tered antigen-specific B  cell foci in the outer PALS was ob- 
served. In contrast,  as illustrated in Fig. 4  B, in mice treated 
with  anti-OX40,  whereas  antigen-specific  B  cells also  oc- 
curred,  they  were  much  less  frequent  and  they  did  not 
form the typical focal structure  in the PALS.  On  the other 
hand,  as shown in Fig. 4,  C-F,  no differences between the 
control  and  anti-OX40-treated  mice  could be  detected  in 
germinal  center  development  evaluated  at  day  11  after 
TNP-KLH  injection  as  assessed  by  anti-IgD  and  PNA 
staining. 
The Effect of Anti-OX40  Treatment  during  a  Secondary  Im- 
mune Response.  In  a  final set  of experiments,  we  investi- 
gated  the relevance of the OX40-OX40L  interaction  dur- 
ing a  primary  immune  reaction  for the  importance  of this 
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immune  response.  For  this  purpose  we  first  immunized 
mice with TNP-KLH and treated them with either rabbit 
IgG or with anti-OX40 antibodies; the results of these ex- 
periments were  shown  above. After 4  mo  the  mice were 
reimmunized and  either not  treated with  any antibody at 
all or treated as described for the primary immunization. As 
illustrated  in  Fig.  5  (top),  the  secondary immune response 
after treatment with anti-OX40 at the time of the primary 
antigenic  challenge only was not altered in comparison to 
control-treated  mice.  However,  as  depicted  in  Fig.  5  as 
well  (bottom),  when  these  animals  were  also  treated  with 
anti-OX40 antibodies during the secondary immunization, 
a complete inhibition  of the secondary IgG1 response was 
observed. 
Discussion 
OX40 is a member of the NGFR/TNFR  superfamily of 
receptors expressed on activated T  cells which, upon cross- 
linking,  results in  enhanced  T  cell proliferation and cyto- 
kine secretion (11,  16,  17).  Its ligand,  OX40L, is found on 
activated B  cells and, in a recent study we showed that the 
cross-linking of OX40L in  vitro  results  in  a  dramatic in- 
crease in B cetI proliferation and secretion of all Ig isotypes 
(13).  This latter effect was independent of a number of in- 
vestigated cytokines (IL-2, IL-4, IL-5, IL-6, and IL-10) and 
was due to an increased per cell  Ig secretion rate. As expla- 
nation for this effect on Ig secretion, we provided evidence 
that OX40L cross-linking on the B  cell surface results in a 
change in the binding of specific transcription factors to the 
Ig heavy chain 3'or enhancer, which results in enhancer ac- 
tivation and increased Ig gene transcription (13,  18). 
In the present study, we examined the importance of the 
OX40-OX40L interaction to a T  cell-dependent B cell re- 
sponse in vivo. First,  we showed that OX40  is maximally 
expressed on T  cells  within the PALS 3  d after immuniza- 
tion with TNP-KLH. This peak in  OX40  expression falls 
within the time flame and localization in which the T  ceU-B 
cell interaction is believed to take place in the spleen (19). 
Previous studies (20) have established that the expression of 
CD40L  and  the  production  of several  cytokines  in  vivo 
reach their maximum in the same time period. It should be 
noted that, whereas the expression of CD40L by activated 
T  ceils in vitro is only detectable for a very short period of 
time (21,  22), the expression of OX40 by activated T  cells 
in vitro peaks after 24  h  and stays upregulated  for at least 
five consecutive days. Although  OX40 was not detectable 
after day 4  in vivo, it is possible that it was still  expressed 
but  not  detectable by our antibody because  of an  intense 
interaction with OX40L on activated B  cells  or the release 
of  soluble  OX40L,  which  either  blocks  certain  OX40 
epitopes or leads to an internalization  of OX40 molecules 
on T  cells.  Similar mechanisms are also believed to render 
the in vivo detection of CD40L by certain antibodies im- 
possible (23,  24). 
Second, we demonstrated that OX40-expressing T  cells 
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are in  close proximity to specific AFCs in  the  PALS  that 
have previously been shown to stain positively for OX40L 
(12).  Therefore, an actual interaction  through the  OX40- 
OX40L receptor-ligand pair is quite likely. 
Third, we showed that this OX40-OX40L interaction is 
critical for the in vivo T  cell-dependent humoral immune 
response. Thus, blocking this interaction with three differ- 
ent  systemically administered  anti-OX40  antibodies  each 
caused a profound (anti-OX40, anti-P-OX-2) or moderate 
(anti-P-OX-1)  inhibition  of the  specific  IgG response  to 
concomitantly administered antigen  (TNP-KLH). This ef- 
fect was specific for the T  cell-dependent B  cell response, 
since the anti-TNP response elicited by immunization with 
treatment  only 
during  1st 
immunization 
rabbit IgG 
anti-OX40 
unizatlon 
￿9  7  days after 2rid immunization 
01  02  0,3  0.4  05  0.6 
O.D. 
Figure 5.  The administration of anti-OX40 inhibits the production of 
antigen-specific lgG when given during a secondai  3, immunization. 4 mo 
after the primary immunization with TNP-KLH and the apphcation of 
rabbit lgG or anti-OX40, BALB/c mice were reimmunized with 100 p,g 
i.p. TNP-KLH in IFA. The animals were subsequently not treated at all 
(top)  or treated  the same way as during the primary immunization (bot- 
tom).  Serum was collected 7  d  after the secondary challenge and TNP- 
specific IgG1 was determined as described in Materials and Methods. Re- 
sults  depict  the  OD490  readings  for  anti-TNP-IgG1.Control  animals, 
which  received  TNP-KLH  in  IFA  for  the  first  time,  produced  about 
three times lower anti-TNP-IgG1 serum levels at day 7 compared to ani- 
mals immunized for the second time with the same antigen, with the pri- 
mary immunization consisting of TNP-KLH in CFA (data not shown). T  cell-independent antigens  (TNP-Ficoll [TI-2] or TNP- 
LPS [TI-1]) was not affected by the administration ofanti- 
OX40. Furthermore, the effect of the anti-OX40 antibod- 
ies was  not due to complement-mediated lysis of T  cells, 
since we did not observe a decrease in cytokine-secreting T 
cells as assessed by immunohistochemical staining for IL-2, 
IFN-',/, IL-4, and IL-5. This and the .fact that germinal cen- 
ter development and IgM response was not impaired indi- 
cate that the activated T  cells targeted by anti-OX40 were 
still  intact.  It is  of special interest that  the production of 
specific IgM was  not altered by anti-OX40  antibody ad- 
ministration.  This could be due to an inhibitory effect of 
anti-OX40 on Ig isotype switching, but this seems unlikely 
for several reasons.  First,  in  our prior in vitro studies we 
could not detect any influence of OX40 on isotype switch- 
ing. In addition, the effect of OX40L cross-linking was ob- 
served only after 5 d of culture, considerably after switch- 
ing had occurred. Finally, if anti-OX40 antibodies inhibit 
switching, one would expect an increased rather than un- 
changed IgM antibody response, as seen in patients with a 
specific genetic defect resulting in a dysfunctional CD40L 
molecule (hyper-IgM syndrome; 25-28).  In view of this, 
the lack of effect of anti-OX40 antibodies on the produc- 
tion of  specific IgM is more likely due to the fact that B cell 
stimulation through CD40L plus cytokines is sufficient for 
the production of IgM in the first 6 d after immunization. 
After that, most of the cells have switched and apparently 
do need another stimulus for high level Ig secretion, pre- 
sumably because  cytokine  expression after  day  4  is  very 
low, as shown in previous studies (20, and our unpublished 
observations). 
Finally, we showed that a secondary response to TNP- 
KLH was not altered by administration of anti-OX40 anti- 
bodies during the primary immunization. Although adop- 
tive transfer experiments to formally prove this point have 
not yet been done, these data suggest that anti-OX40 treat- 
ment does not prevent the development of B cell memory. 
This is in contrast to the results  obtained in the studies  us- 
ing  an  anti-gp39  (anti-CD40L)  antibody during  primary 
immunization,  since in this  case  anti-gp39 inhibited both 
the  primary and secondary immune  responses  (8).  How- 
ever, when we administered anti-OX40 during a secondary 
immunization,  we  found that  the  secondary immune  re- 
sponse is also dependent on the OX40-OX40L interaction. 
The results obtained by the administration ofanti-OX40 
antibodies have implications for our current understanding 
of B  cell  differentiation  in  vivo.  Primary  immunization 
with a T  cell-dependent antigen results in two pathways of 
B  cell  differentiation:  the  extrafollicular pathway,  which 
leads to an early antibody response, and the germinal center 
pathway,  in  which  somatic  mutation,  memory  develop- 
ment, but also plasma  cell differentiation, occur (1, 4, 29). 
A  number of authors have suggested that these two path- 
ways are interconnected (3,  19),  whereas others have sug- 
gested that they are dependent on the presence of distinct B 
cell precursors, which can be distinguished by their expres- 
sion  of HSA:  HSA1ow B  cells  develop into memory cells, 
whereas HSAhig  h B  cells become antibody-producing cells 
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(10).  This theory, however, is opposed by studies by All- 
man et al.  (30),  who showed that HSAhig  h cells are imma- 
ture B cells that do not serve as precursors for any particular 
B cell differentiation pathway. In addition, this theory is at 
odds with the finding that the same rare CDR3 mutation is 
shared by cells in the PALS and in the germinal centers (3). 
Regardless of which of the above mentioned hypotheses is 
true, the presented data on the effect ofanti-OX40 admin- 
istration suggest that OX40--OX40L interaction is crucial 
for the development of antibody-secreting cells,  indepen- 
dent of their presumed origin. 
Previous studies  that  investigated  the  role  of T  cell-B 
cell interaction in vivo using antibodies against specific stim- 
ulatory surface molecules on the T  cell (CD40L) (8) or on 
the B cell (B7-1/B7-2) (5-7) demonstrated the importance 
of these receptor-ligand pairs  in the early phases  of B  cell 
activation in vivo. Both early antibody response and germi- 
nal center formation--and thereby B  cell memory devel- 
opment-were  impaired.  One  previous study reported a 
selective block of the occurrence of one of the two differ- 
ent B  cell differentiation pathways:  Pulendran  et  al.  (31) 
were able to demonstrate that the application of soluble an- 
tigen before injection of aggregated antigen inhibits prefer- 
entially the appearence of specific germinal centers and B 
cell memory development.  The authors  did not  offer an 
explanation for this effect. However, it could be that the 
application of soluble  antigen interferes with  the  interac- 
tion of activated B  cells with the  antigen-antibody com- 
plexes on follicular dendritic cells, which are known to be 
important for the formation of germinal center (29). 
The results  of the present study, however, indicate that 
the OX40-OX40L interaction might be of special  impor- 
tance for the development of antibody-secreting cells but 
not for the formation of germinal centers. We underlined 
this  theory by  demonstrating  a  reduced  development  of 
PALS-associated B cell foci specific for TNP in addition to 
the almost total abolishment of the specific anti-TNP IgG 
response.  On  the  other hand,  the development of peanut 
agglutinin-positive, IgD- germinal centers remained intact, 
as  did B  cell memory differentiation, as suggested in sec- 
ondary immunization studies. 
The present data and data from previous studies allow us 
to postulate a modified view of the events occurring during 
the course of a T  cell-dependent B cell response, which is 
summarized in  Fig.  6.  2-4  d  after primary immunization 
with  a  T  cell-dependent  antigen,  B  cells  interact  with 
CD40L on activated T  cells and are also  stimulated by T 
helper 2-type cytokines to secrete IgM and to undergo the 
initial steps  of Ig isotype switching (29,  32).  Whereas the 
CD40L signal  is  the  crucial activation step  for Ig isotype 
switching and subsequent B  cell differentiation events (8), 
the early IgM response does not seem to be totally depen- 
dent  upon  this  stimulus,  since  patients  with  hyper-IgM 
syndrome secrete large amounts  of IgM  after Ig receptor 
cross-linking and help from cytokines in the absence of a 
functional CD40L molecule expressed on activated T  cells 
(33).  This is also in accordance with in vitro studies show- 
ing that Ig receptor cross-linking together with, for exam- 
OX40--OX40L Interaction Is Necessary for T-dependent Immune Responses Figure 6.  Model for the role of the OX40-OX40L interaction during the course of T-dependent  B cell differentiation in vivo. See Discussion for 
details. 
pie, IL-5 in the absence of CD40L,  is sufficient to cause Ig 
secretion  (34). 
The  next step in B  cell differentiation  involves the  for- 
mation of PALS-associated B  cell loci and germinal centers. 
In  either  case, B  cells interact  with  OX40  on  activated  T 
cells, which is critical for high level Ig production,  presum- 
ably because this interaction leads to an activation of the Ig 
heavy  chain  3'0~  enhancer  (13).  We  do  not  know  at  this 
point if it is (a) sufficient for the cells that form the germinal 
centers  to receive the  OX40  signal before they migrate to 
the  follicles,  which  only  becomes  apparent  after  some  of 
the differentiated cells leave the germinal centers and emerge 
as plasma cells,  or if (b) cells leaving the germinal centers to 
form  plasma  cells  have  to  receive  an  additional  stimulus 
through  OX40L,  as suggested in Fig. 6. This latter possibil- 
ity cannot be ruled out, because of the long-lasting expres- 
sion  of OX40  on  activated  T  cells in  vitro.  In  any event, 
the OX40--OX40L  interaction  cannot be circumvented by 
cytokines  as shown  by our in vitro studies  and  by the  fact 
that  the  IgG  responses  are  completely  abrogated  by  anti- 
OX40  administration,  which  does  not  result  in  a  decrease 
of cytokine-producing  T  cells.  It should be noted that this 
view does not deny the important role of certain cytokines, 
especially IL-6, in the  terminal  differentiation  of B  cells as 
demonstrated in IL-6 knockout mice (35). We suggest that 
these  cytokines,  which  in  the  case  of IL-6  are  also  pro- 
duced by activated macrophages and B  cells  (36), probably 
act after the neccessary OX40 stimulus and drive the B  cells 
into  fully  differentiated  plasma  cells,  which  cannot  be  ac- 
comphshed by the cross-hnking of OX40L alone (13). 
Finally, it is important to add that so far only the OX40- 
OX40L interaction,  which occurs between activated T  cells 
and activated B  cells,  ensures that activated T  cells express- 
ing  CD40L  do  not  stimulate  B  cells  through  interaction 
with  CD40,  which  is  constitutively  expressed  on  B  cells. 
Thus  activated  T  cells  do  not  have  the  potential  to  cause 
uncontrolled B  cell via bystander activation. 
In conclusion,  we suggest that at least two T  cell-B  cell 
surface interactions  must  occur before  the B  cell  can pro- 
duce  large  amounts  of IgG antibodies  in  response  to  a  T 
cell--dependent antigen,  One involving CD40L-CD40  leads 
to Ig isotype switching and is crucial for all subsequent B  cell 
differentiation  events; another involving OX40--OX40L  al= 
lows B  cells to produce  large amounts  of Ig. Further  work 
defining the role of this second interaction  in immunodefi- 
ciencies and autoirnmunity is currently in progress. 
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